Compare Humana Inc (HUM) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Weibo Corp — how do they compare? Humana Inc trades at $444.98 (market cap $47.61B), while Weibo Corp trades at $6.46 (market cap $1.57B). The key difference: Humana Inc is far larger — about 30.3× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (9.41%). Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Weibo Corp for 102 Days on average.
| HUM | WB | |
|---|---|---|
Market Cap | $47.61B | $1.57B |
Volume | 1,827,332 | 947,144 |
Sector | Health | Media |
52-Week High | $409.85 | $12.37 |
52-Week Low | $163.67 | $6.33 |
Typical Hold Time | 53 Days | 102 Days |
Enterprise Value | $54.97B | $799.15M |
Dividend Yield | 0.89% | 9.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $387.12, down 4.24% today, but maintains a bullish technical outlook with strong institutional support. The stock shows mixed fundamentals with revenue growth to $129.66B in 2025 but declining profit margins at 0.88%. Recent analyst upgrades, including Barclays' $515 target on September 25, 2026, highlight optimism despite ongoing Medicare Advantage plan adjustments affecting member transitions.
Investment outlook remains cautiously optimistic with a consensus price target of $432.63 offering 12% upside. Risks include margin compression, regulatory scrutiny from Medicare billing practices, and competitive pressures in managed care. The company's strong cash position of $20.44B and consistent dividend payments provide stability amid enrollment volatility.
Weibo (WB) trades at $6.44, down 0.77% on the day, with a bearish technical signal from moving averages. The stock shows attractive valuation metrics with a P/E of 5.36 and P/B of 0.4, while maintaining strong profitability with 73.36% gross margins and 17.78% net income margin. Recent Q2 2026 earnings beat expectations with $0.38 EPS versus $0.36 expected, though Q1 and Q4 2025 missed estimates. Cash flow trends show volatility, with 2024 net cash flow negative $694 million but improving to positive $408 million in 2025.
Weibo presents a deep-value opportunity with compelling valuation multiples, though growth concerns persist amid declining user metrics and advertising revenue challenges. Analyst sentiment remains mixed with 41% buy ratings versus 45% hold, reflecting uncertainty about the company's ability to maintain relevance against intensifying competition. Key risks include stagnating user growth and advertising market pressures, while the current price offers margin of safety for value-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
